The Uromigos Episode 30: Update on Axitinib Plus Pembrolizumab in Renal Cancer (KEYNOTE 426)

Betsy Plimack discusses the updated data with a minimum of 23 months’ follow up. Drs. Brian Rini and Tom Powles asks what it adds.